Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target hoisted by Scotiabank from $49.00 to $52.00 in a research ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...

Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

But the direct-to-consumer ad didn't come from Palo Alto-based Bridge Bio (Nasdaq: BBIO); instead it was produced by Pfizer ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...